In yesterday’s Wall Street session, Viatris Inc (NASDAQ:VTRS) shares traded at $11.57, down -1.78% from the previous session.
VTRS stock price is now -3.70% away from the 50-day moving average and 7.31% away from the 200-day moving average. The market capitalization of the company currently stands at $13.78B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $13 to $9, BofA Securities Downgraded its rating from Neutral to Underperform for Viatris Inc (NASDAQ: VTRS). On June 23, 2023, Barclays Downgraded its previous ‘Equal Weight’ rating to ‘Underweight’ on the stock keeping its target price maintained at $11, while ‘BMO Capital Markets’ rates the stock as ‘Market Perform’
In other news, Mauro Anthony, insider sold 250,000 shares of the company’s stock on Mar 13 ’24. The stock was sold for $3,023,700 at an average price of $12.09. Upon completion of the transaction, the insider now directly owns 243,044 shares in the company, valued at $2.81 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 05 ’24, Campbell Paul sold 24,353 shares of the business’s stock. A total of $300,272 was realized by selling the stock at an average price of $12.33. This leaves the insider owning 153,826 shares of the company worth $1.78 million. A total of 2.01% of the company’s stock is owned by insiders.
During the past 12 months, Viatris Inc has had a low of $8.74 and a high of $13.62. As of last week, the company has a debt-to-equity ratio of 0.90, a current ratio of 1.57, and a quick ratio of 1.13.
According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at 0.77, beating analysts’ expectations of 0.69 by 0.08. This compares to $0.83 EPS in the same period last year. The net profit margin was 0.36% and return on equity was 0.26% for VTRS. The company reported revenue of $3.84 billion for the quarter, compared to $3.88 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.0 percent. For the current quarter, analysts expect VTRS to generate $3.69B in revenue.
